Updated with comment from Novartis spokesperson.
Someone at Novartis (NVS - Get Report) screwed up today by sending out a mass email announcing the FDA approval of a new lung cancer drug ceritinib. Brand name: Zykadia. The only problem is FDA hasn't announced the approval of Zykadia yet.
Here's an image from the Novartis email sent out by accident, then asked to be retracted. Of course, nothing can be truly retracted these days.
Zykadia is Novartis' ALK inhibitor, which was approved as second-line therapy for patients with ALK-positive lung cancer. It will be used behind Pfizer's (PFE - Get Report) ALK inhibitor Xalkori.
Ariad Pharmaceuticals (ARIA - Get Report) and Roche/Chugai also have ALK inhibitors in clinical trials.
The pivotal study of Zykadia was recently published in the New England Journal of Medicine.
Update: A Novartis spokesperson emails:
The US Food and Drug Administration is in the process of reviewing a New Drug Application for ceritinib. No FDA approval has been obtained to date. The email that was distributed on April 10 was sent in error by Inspire, an online health community.
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/05/15 - 10:40 AM EDT
09/02/15 - 19:12 PM EDT
09/02/15 - 08:59 AM EDT
09/01/15 - 08:32 AM EDT
08/31/15 - 01:03 AM EDT
08/31/15 - 01:01 AM EDT
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.